{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-051441","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.209667+00:00","generated_at":"2026-05-24T23:56:10.610261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront","bullets":["Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.","Cash $55.3M at Dec 31, 2024; plus $52M AbbVie upfront in Q1 2025 extends runway into Q1 2026.","Vilastobart Phase 2 in MSS CRC: 27% ORR in patients without liver metastases; colitis 5%.","Collaboration with AbbVie: up to $2.1B total payments plus royalties; develop masked T cell engagers.","Plan to nominate development candidates for PSMA (Q3 2025), CLDN18.2 (Q4 2025), STEAP1 (H1 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-051441","json":"https://secwatch.observer/filing/0001193125-25-051441.json","markdown":"https://secwatch.observer/filing/0001193125-25-051441.md","text":"https://secwatch.observer/filing/0001193125-25-051441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/0001193125-25-051441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/d890896d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:56:10.610261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}